All Stories

  1. Editorial: New molecular targets involved in lung adenocarcinoma
  2. Integrated genomic analysis of proteasome alterations across 11,057 patients with 33 cancer types: clinically relevant outcomes in framework of 3P medicine
  3. Introductory Chapter: Metabolomics
  4. Ubiquitin - Proteasome Pathway
  5. SILAC quantitative proteomics analysis of ivermectin‐related proteomic profiling and molecular network alterations in human ovarian cancer cells
  6. Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine
  7. Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment
  8. Integration of quantitative phosphoproteomics and transcriptomics revealed phosphorylation-mediated molecular events as useful tools for a potential patient stratification and personalized treatment of human nonfunctional pituitary adenomas
  9. Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine
  10. Proteoforms - Concept and Applications in Medical Sciences
  11. Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes
  12. Label-free quantitative identification of abnormally ubiquitinated proteins as useful biomarkers for human lung squamous cell carcinomas
  13. Multiomics-Based Signaling Pathway Network Alterations in Human Non-functional Pituitary Adenomas
  14. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles
  15. Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
  16. Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
  17. Energy Metabolism Heterogeneity-Based Molecular Biomarkers for Ovarian Cancer
  18. Innovating the Concept and Practice of Two-Dimensional Gel Electrophoresis in the Analysis of Proteomes at the Proteoform Level
  19. TMT-based quantitative proteomics revealed follicle-stimulating hormone (FSH)-related molecular characterizations for potentially prognostic assessment and personalized treatment of FSH-positive non-functional pituitary adenomas
  20. Identification of clinical trait–related lncRNA and mRNA biomarkers with weighted gene co-expression network analysis as useful tool for personalized medicine in ovarian cancer
  21. Signaling pathway network alterations in human ovarian cancers identified with quantitative mitochondrial proteomics
  22. Quantitative analysis of the mitochondrial proteome in human ovarian carcinomas
  23. The differentially mitochondrial proteomic dataset in human ovarian cancer relative to control tissues
  24. Protein Tyrosine Nitration in Lung Cancer: Current Research Status and Future Perspectives
  25. Exploration of variations in proteome and metabolome for predictive diagnostics and personalized treatment algorithms: Innovative approach and examples for potential clinical application
  26. Prolactin Variants in Human Pituitaries and Pituitary Adenomas Identified With Two-Dimensional Gel Electrophoresis and Mass Spectrometry
  27. The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes
  28. Two-dimensional Gel Electrophoresis Coupled with Mass Spectrometry Methods for an Analysis of Human Pituitary Adenoma Tissue Proteome
  29. The crucial role of multiomic approach in cancer research and clinically relevant outcomes
  30. Every 2D spot contains over 50 to several hundreds of proteins - revival of 2DE-LC/MS in proteomics
  31. Revival of 2DE-LC/MS in Proteomics and Its Potential for Large-Scale Study of Human Proteoforms
  32. Pattern recognition for predictive, preventive, and personalized medicine in cancer
  33. Editorial: Systems Biological Aspects of Pituitary Tumors
  34. Human Pituitary Adenoma Proteomics: New Progresses and Perspectives
  35. Exploration of Molecular Network Variations in Different Subtypes of Human Non-functional Pituitary Adenomas
  36. Proteomic and functional profiles of a follicle-stimulating hormone positive human nonfunctional pituitary adenoma
  37. EPMA position paper in cancer: current overview and future perspectives
  38. Heterogeneity analysis of the proteomes in clinically nonfunctional pituitary adenomas
  39. Identification of the proteomic variations of invasive relative to noninvasive nonfunctional pituitary adenomas
  40. Multi-parameter systematic strategy opinion that predicts, prevents, and personalized treats a cancer
  41. Mass spectrometry analysis of nitrotyrosine‐containing proteins
  42. Mapping the interactome of overexpressed RAF kinase inhibitor protein in a gastric cancer cell line
  43. Identification of stromal differentially expressed proteins in the colon carcinoma by quantitative proteomics
  44. Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer
  45. Pituitary Adenoma Nitroproteomics: Current Status and Perspectives
  46. Mitochondrial proteomics of nasopharyngeal carcinoma metastasis
  47. Identification of differentially expressed proteins in the spinal cord of neuropathic pain models with PKCgamma silence by proteomic analysis
  48. Proteomic and Bioinformatics Analyses of Mouse Liver Microsomes
  49. The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas
  50. Signaling pathway networks mined from human pituitary adenoma proteomics data
  51. MALDI-induced fragmentation of leucine enkephalin, nitro-Tyr-leucine enkaphalin, and d5-Phe-nitro-Tyr-leucine enkephalin
  52. Detection of Nitrotyrosine-Containing Proteins
  53. Mass Spectrometric Identification of In Vivo Nitrotyrosine Sites in the Human Pituitary Tumor Proteome
  54. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses
  55. The human pituitary proteome: clinical applications
  56. Linear ion-trap mass spectrometric characterization of human pituitary nitrotyrosine-containing proteins
  57. Nitroproteins from a human pituitary adenoma tissue discovered with a nitrotyrosine affinity column and tandem mass spectrometry
  58. Proteomics analysis of growth hormone isoforms in the human pituitary
  59. Comparative proteomics analysis of human pituitary adenomas: Current status and future perspectives
  60. The human pituitary nitroproteome: detection of nitrotyrosyl-proteins with two-dimensional Western blotting, and amino acid sequence determination with mass spectrometry
  61. Heterogeneity Analysis of the Human Pituitary Proteome
  62. Comparative proteomics analysis of human lung squamous carcinoma
  63. Differences in the spatial and quantitative reproducibility between two second-dimensional gel electrophoresis systems
  64. Spot volume vs. amount of protein loaded onto a gel: A detailed, statistical comparison of two gel electrophoresis systems
  65. A reference map of a human pituitary adenoma proteome
  66. Proteomics and Transcriptomics Analyses of Secretagogin Down-Regulation in Human Non-Functional Pituitary Adenomas